Effect of ecabet sodium treatment on urea breath test and stool antigen tests in volunteers with Helicobacter pylori infection.

BACKGROUND AND AIM: Ecabet sodium is reported to have a bactericidal effect on Helicobacter pylori and inhibit urease activity in vitro. METHODS: Seven male volunteers (mean age, 51.3 years; range, 45-55 years) with H. pylori infection were medicated with 1 g ecabet sodium t.i.d. for 4 weeks. The urea breath test (UBT) was performed 10 times per person: before medication, seven times in 2 weeks, and once in the third and fourth weeks. Stool antigen tests (HpSA PLUS and Testmate pylori antigen) were performed five times per person: before medication and weekly during medication. RESULTS: The premedication UBT value ranged from 4.9 ‰ to 77.4 ‰ and from 2.9 ‰ to 44 ‰ at the end of the treatment period. Not one of the subjects had a negative UBT result during medication. The optical densities of the HpSA and Testmate pylori antigen tests ranged from 0.4 to > 3.0 premedication and from 0.0 to > 3.0 at the end of treatment. HpSA and Testmate pylori antigen were negative in two cases. CONCLUSIONS: In this study, ecabet sodium did not effect the results of UBT in volunteers with H. pylori infection. Ecabet sodium may influence stool antigens because in two of seven cases the H. pylori stool antigen tests returned negative results.

Dietary antigens in Crohn's disease: antibodies to porcine pancreatic amylase.

OBJECTIVES: There is no clear evidence that dietary proteins aggravate Crohn's disease (CD). We aimed to clarify the antibody response to dietary proteins in CD. METHODS: Antibody to porcine pancreatic amylase (PPA) a protease-resistant dietary protein (anti-PPA), was examined in CD patients (N = 104), ulcerative colitis (UC) patients (N = 85), and healthy controls (N = 83), and its relationship with the clinical characteristics of CD was investigated. Antibodies to casein and ovalbumin, anti-Saccharomyces cerevisiae antibodies (ASCA), and antibodies to I2 from Pseudomonas fluorescens (anti-I2) were also examined. RESULTS: Thirty-eight percent (39/104) of the CD patients expressed anti-PPA antibodies, and this percentage was significantly higher as compared with the control group (5%, 4/83) and the UC group (9%, 8/85) (P < 0.001). A significantly higher level of anti-PPA antibodies was detected in patients with "small bowel disease-dominant" CD than in those with "colitis-dominant" CD (P < 0.05). Antibodies to casein and ovalbumin were not specifically expressed in CD patients. As ASCA was detected in 33% and anti-I2 in 46% of the CD patients, 72% of the CD patients were found positive for at least one of the three antibodies including anti-PPA antibodies. CONCLUSIONS: CD patients showed a specific antibody response to PPA, as compared with UC patients and controls. There was a significantly higher level of anti-PPA antibody in patients with "small bowel disease-dominant" CD, suggesting that dietary proteins could play a role in the inflammatory response in CD patients with small bowel disease. Anti-PPA antibodies combined with ASCA/anti-I2 may be useful for the diagnosis of CD.

[The range of activities of home enteral and infusion therapy for home medical care at Hyogo College of Medicine].

Our nutrition department has consolidated to become a clinical nutrition department by integrating NST and home enteral and intravenous nutrition supporting nurses into the nutrition department, which deals with a total control of nutrition therapy including diet, infusion and care at hospital and home. The advantages are that nutrition therapy is feasible in addition to nutritional control by the involvement (participation) of physicians, and that it becomes available for a national registered dietitian to counsel on a nutritional control on more clinical bases. Further, a framework has been constructed to perform all the nutritional control and nutrition therapy with proper coordination on hospitalized patients as well as home-care patients.

Helicobacter pylori does not promote N-methyl-N-nitrosourea-induced gastric carcinogenesis in SPF C57BL/6 mice.

Helicobacter pylori (H. pylori) infection has been acknowledged as a promoter and an initiator for gastric carcinogenesis in experimental models using Mongolian gerbils with H. pylori strains TN2GF4 and ATCC 43504, which have + ve cagA and vacA phenotype s1 / m1. To get more insight into the role of H. pylori in gastric carcinogenesis, we studied the effect of H. pylori SS1, which has + ve cagA and vacA phenotype s2 / m2, on N-methyl-N-nitrosourea (MNU)-induced chemical gastric carcinogenesis using SPF C57BL / 6 mice. Thus, H. pylori SS1 was inoculated 1 week after the completion of MNU treatment to examine the promoting effect of this bacterium. The incidences of polypoid lesions, differentiated adenocarcinomas, and adenomatous hyperplasias were 67% (10 / 15), 47% (7 / 15) and 80% (12 / 15), respectively, in the MNU-alone group. The corresponding figures were 31% (8 / 26), 23% (6 / 26) and 35% (9 / 26) in the MNU + H. pylori group. The incidences of polypoid lesions and adenomatous hyperplasia were significantly different between the groups. Thus, the results indicate that H. pylori SS1 infection reduced susceptibility to chemical gastric carcinogenesis in this model. The discrepancy between the present result and previous results is likely to have been caused by differences in host factors and bacterial factors. Further study of the relationship between gastric carcinogenesis and H. pylori infection is needed.